e-learning
resources
Paris 2018
Monday, 17.09.2018
Clinical management of pleural malignancies, including mesothelioma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The clinical benefits of immune checkpoint inhibitors for thymic carcinomas
N. Uchida (Kyoto, Japan), K. Fujita (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan)
Source:
International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Session:
Clinical management of pleural malignancies, including mesothelioma
Session type:
Thematic Poster
Number:
2878
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Uchida (Kyoto, Japan), K. Fujita (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan). The clinical benefits of immune checkpoint inhibitors for thymic carcinomas. 2878
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Imaging of complicated pneumonia: what is new?
Emerging classes of drugs for the treatment of obstructive lung disease
Related content which might interest you:
The efficacy of immune checkpoint inhibitors in thoracic malignancies
Source: Eur Respir Rev, 30 (162) 200387; 10.1183/16000617.0387-2020
Year: 2021
Immune checkpoint inhibitors in lung cancer
Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine
Year: 2016
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019
Year: 2019
The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents
Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside
Year: 2020
Predictive biomarker of immune checkpoint inhibitors efficacy
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Year: 2019
Management of pulmonary toxicity associated with immune checkpoint inhibitors
Source: Eur Respir Rev, 28 (154) 190012; 10.1183/16000617.0012-2019
Year: 2019
Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017
The role of STAT3 in T-cell responses during the development of NSCLC
Source: International Congress 2017 – Lung cancer - basic science: the latest results from the bench
Year: 2017
From ineffective tumor immune response to immunomodulation in lung cancer
Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies?
Year: 2017
Evaluation of serial interferon-gamma release assay testing in lung cancer patients treated with immune checkpoint inhibitors
Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis
Year: 2021
Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study
Source: ERJ Open Res, 6 (1) 00165-2019; 10.1183/23120541.00165-2019
Year: 2020
NTHi-induced inflammation activates the PD-1 immune checkpoint in the tumor microenvironment
Source: International Congress 2018 – Lung cancer: novel molecular markers and mechanisms
Year: 2018
Preliminary evaluation of serial interferon-gamma releasing assay testing in NSCLC patients treated with immune checkpoint inhibitors
Source: Virtual Congress 2020 – Tuberculosis: part 2
Year: 2020
The role of epithelial Pten in programmed cellular senescence during lung development
Source: International Congress 2018 – Molecular and cellular determinants of the developing lung
Year: 2018
The PD-1 immune checkpoint promotes lung damage in murine models of COPD-like inflammation
Source: International Congress 2019 – Injury and repair: less is more
Year: 2019
The role of NFATc1 in T cell responses during the development of NSCLC
Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells
Year: 2017
Long-term outcomes and prognostic factors for neuroendocrine G1 and G2 lung tumors
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
A case of pulmonary tuberculosis development after receiving immune check point inhibitor in an advanced non-small cell lung cancer
Source: International Congress 2019 – Lung cancer?
Year: 2019
Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas
Source: Eur Respir J 2004; 24: Suppl. 48, 557s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept